You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • THU0140 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme

Citation Tools

Article menu
Download PDFPDF
Scientific Abstracts
Poster Presentations
Posters
Rheumatoid arthritis – non-biologic treatment and small molecules
THU0140 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Lee E, Curtis J, Riese R, et al
THU0140 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of gastrointestinal adverse events across the rheumatoid arthritis clinical programme
Annals of the Rheumatic Diseases 2013;71:202-203.